<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0604221922
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Gizamlo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        61.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Gizamlo<sup>&reg; </sup></strong>contains two substances called irbesartan and amlodipine. Both of these substances help to control high blood pressure.</p><p>- Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax.</p><p>- Amlodipine belongs to a group of substances called &ldquo;calcium channel blockers&rdquo;. Amlodipine stops calcium from moving into the blood vessel wall which stops the blood vessels from tightening.</p><p><strong>Gizamlo<sup>&reg; </sup></strong>is indicated in the treatment of hypertension in adult patients in whom blood pressure is not adequately controlled on irbesartan or amlodipine monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Gizamlo<sup>&reg;</sup></strong></p><p>As the drug contains both irbesartan and amlodipine, <strong>Gizamlo<sup>&reg;</sup></strong> is contraindicated in:</p><p>- patients allergic to either or both of the active substances or to any of the ingredients of the drug.</p><p>- patients allergic to dihydropyridines.</p><p>- patients with cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal&rsquo;s angina).</p><p>- pregnancy and lactation.</p><p><strong>Gizamlo<sup>&reg;</sup></strong> should not be administered concomitantly with medicinal products containing aliskiren in patients with diabetes or moderate to severe renal insufficiency (glomerular filtration rate [GFR] &lt; 60 mL/min/1.73 m2).</p><p>&nbsp;</p><p><strong>Warnings and Precautions </strong></p><p><em><u>Hypotension:</u></em> volume-depleted patients: Irbesartan has been rarely associated with hypotension in hypertensive patients without other co-morbid conditions. As with ACE inhibitors, symptomatic hypotension may be expected to occur in sodium / volume - depleted patients and in those undergoing intensive diuretic treatment and/or salt restriction, or on hemodialysis. Volume and/or sodium depletion should be corrected before therapy with <strong>Gizamlo<sup>&reg;</sup></strong> is initiated or the lowest possible starting dose should be considered.</p><p>&nbsp;</p><p><em><u>Fetal/neonatal morbidity and mortality:</u></em> Although there is no experience with irbesartan in pregnant women, in utero exposure to ACE inhibitors given to pregnant women during the second and third trimesters of gestation has been reported to cause injury to and death of the developing fetus. Thus, as for any drug that acts directly on the renin-angiotensin-aldosterone system, <strong>Gizamlo<sup>&reg;</sup></strong> should not be used during pregnancy. If pregnancy is detected during treatment, <strong>Gizamlo<sup>&reg;</sup></strong> should be discontinued as soon as possible.</p><p>&nbsp;</p><p><em><u>Patients with heart failure: </u></em>Amlodipine was associated with increased reports of pulmonary edema in patients with NYHA III and IV heart failure of nonischemic etiology, despite no significant difference in the incidence of worsening of heart failure compared to placebo.</p><p>&nbsp;</p><p><em><u>Hepatic impairment:</u></em> As with other calcium antagonists, amlodipine half-life is prolonged in patients with impaired liver function and no dosage recommendations have been established in this population. <strong>Gizamlo<sup>&reg;</sup></strong> should therefore be administered with caution in these patients.</p><p>&nbsp;</p><p><em><u>Hypertensive crisis:</u></em> The safety and efficacy of Irbesartan/Amlodipine in the treatment of hypertensive crisis have not been established.</p><p>&nbsp;</p><p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with aliskiren-containing medicinal products:</u></em> the dual blockade of the renin-angiotensin-aldosterone system induced by administration of the Irbesartan/Amlodipine + aliskiren combination is not recommended as there is an increased risk of hypotension, hyperkalemia and impairment of renal function. Use of the Irbesartan/Amlodipine + aliskiren combination is contraindicated in patients with diabetes mellitus or with renal insufficiency (glomerular filtration rate [GFR] &lt;60 mL/min/1.73 m2).</p><p>As a consequence of blocking the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function is dependent on renin-angiotensin-aldosterone system activity (hypertensive patients with renal artery stenosis in one or both kidneys, or patients with severe congestive heart failure), treatment with other drugs that affect this system has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. The possibility of a similar effect occurring with the use of an angiotensin II receptor antagonist, including irbesartan, cannot be ruled out.</p><p>&nbsp;</p><p><em><u>Geriatric use:</u></em> In patients who received irbesartan in clinical studies. No overall differences in efficacy or safety were observed between older patients (65 years or older) and younger patients.</p><p>&nbsp;</p><p><em><u>Pediatric use:</u></em> The safety and efficacy of Irbesartan/Amlodipine have not been established in pediatric patients.</p><p>&nbsp;</p><p><strong>Taking other medicines, herbal or dietary supplements</strong></p><p><em><u>For the irbesartan and amlodipine combination: </u></em>Based on a pharmacokinetic study where irbesartan and amlodipine were administered alone or in combination, there is no pharmacokinetic interaction between irbesartan and amlodipine. No drug interaction studies have been performed with irbesartan/amlodipine and other medicinal products.</p><p>&nbsp;</p><p><em><u>Irbesartan:</u></em> Based on in vitro data, no interactions would be expected to occur with drugs for which metabolism depends on cytochrome P450 isoenzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1 or CYP3A4. Irbesartan is primarily metabolized by CYP2C9, however, during clinical interaction studies no significant interactions were observed when irbesartan was co-administered with warfarin (metabolized by CYP2C9). Co-administration with nifedipine or hydrochlorothiazide has no effect on the pharmacokinetic profile of irbesartan. Irbesartan has no effect on the pharmacokinetics of simvastatin (metabolized by CYP3A4) or digoxin (substrate of P-glycoprotein efflux transporter). Based on experience with the use of other drugs with an effect on the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase serum potassium levels.</p><p>Use of <strong>Gizamlo<sup>&reg;</sup></strong> concomitantly with medicinal products containing aliskiren is contraindicated in patients with diabetes mellitus or moderate to severe renal insufficiency (glomerular filtration rate [GFR] &lt;60mL/ min/1.73m2), and is not recommended in other patients. In elderly patients, volume-depleted patients (including those treated with diuretics), or in patients with impaired renal function, co-administration of irbesartan with NSAIDs, including selective COX-2 inhibitors, or with angiotensin II receptor antagonists, including irbesartan, can cause deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Renal function should be monitored periodically in patients receiving occasional treatment with irbesartan and NSAIDs. The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.</p><p>&nbsp;</p><p><em><u>Amlodipine:</u></em> Amlodipine has been safely co-administered with thiazide diuretics, beta blockers, alpha blockers, ACE inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, NSAIDs, antibiotics, and oral hypoglycemic drugs.</p><p>Data from in vitro studies with human plasma indicate that amlodipine has no effect on the protein binding of the medicinal products studied (digoxin, phenytoin, warfarin or indomethacin).</p><p>Cimetidine: Co-administration of amlodipine with cimetidine had no effect on the pharmacokinetic profile of amlodipine.</p><p>Grapefruit juice: Co-administration of 240 mL of grapefruit juice with a single 10 mg oral dose of amlodipine had no significant effect on the pharmacokinetics of Amlodipine.</p><p>Aluminum / magnesium (antacids): Concomitant administration of an antacid containing aluminum / magnesium with a single dose of amlodipine had no significant effect on the pharmacokinetic profile of amlodipine.</p><p>Sildenafil: When amlodipine and sildenafil were used in combination, each agent independently exerted a blood pressure lowering effect.</p><p>Atorvastatin: Co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.</p><p>Digoxin: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in healthy subjects.</p><p>Warfarin: Co-administration of amlodipine did not significantly change the effect of warfarin on prothrombin time.</p><p>Cyclosporine: Pharmacokinetic studies with cyclosporine have demonstrated that amlodipine has no significant effect on cyclosporine pharmacokinetics.</p><p>&nbsp;</p><p><strong><u>Irbesartan</u></strong><u>:</u></p><p>No carcinogenic evidence was observed with administration of irbesartan at doses of up to 500/1000 mg/kg/day in rats (male/female, respectively) and 1000 mg/kg/day in mice for 2 years. These doses provided a systemic exposure 4-25 times (rats) and 4-6 times (mice) the exposure in humans receiving 300 mg/day. Irbesartan was not mutagenic in a battery of in vitro tests (Ames microbial test, rat hepatocyte DNA repair test, V79 mammalian-cell forward gene-mutation assay). Irbesartan was negative in several tests for induction of chromosomal aberrations (in vitro human lymphocyte assay; in vivo mouse micronucleus study). Fertility and reproductive performance were not affected in studies of male and female rats, even at doses causing some parental toxicity (up to 650 mg/kg/day).</p><p>No significant effects on the number of corpora lutea, implants, or live fetuses were observed. Irbesartan had no effect on survival, development, or reproduction of offspring.</p><p>Transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous edema) were observed in rat fetuses at doses of 50 mg/kg/day or higher, which resolved after birth. In rabbits, maternal mortality, abortion and early resorption were observed at doses of 30 mg/kg/day.</p><p>No other teratogenic effects were observed in rats or rabbits.</p><p>&nbsp;</p><p><strong><u>Amlodipine:</u></strong></p><p>Carcinogenesis: Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25 and 2.5 mg/kg/day showed no evidence of carcinogenicity, the highest dose (similar to the maximum recommended human dose of 10 mg on a mg/m2 basis for mice, and about twice* this maximum dose for rats) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenesis: Mutagenesis studies revealed no amlodipine - related effects at either the gene or chromosome levels.</p><p>Infertility: There was no effect on fertility in rats treated with amlodipine at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis).</p><p>* (based on a 50 kg patient)</p><p>&nbsp;</p><p><strong>Gizamlo<sup>&reg;</sup> with food and drink.</strong></p><p><strong>Gizamlo<sup>&reg;</sup></strong> can be administered with or without food.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><em><u>Pregnancy:</u></em> There are no adequate and well-controlled studies in pregnant women. Irbesartan/Amlodipine is contraindicated during pregnancy. <strong>Gizamlo<sup>&reg;</sup></strong> must not be administered to women of childbearing potential unless effective contraception is used.</p><p>When pregnancy is detected during treatment, <strong>Gizamlo<sup>&reg;</sup> </strong>should be discontinued as soon as possible.</p><p>&nbsp;</p><p><em><u>Lactating mothers:</u></em> <strong>Gizamlo<sup>&reg;</sup></strong> is contraindicated during lactation.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>Gizamlo<sup>&reg; </sup></strong>exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The usual initial and maintenance dose of <strong>Gizamlo<sup>&reg;</sup></strong> is one tablet per day.</p><p><strong>Gizamlo<sup>&reg;</sup></strong> can be administered with or without food.</p><p><strong>Gizamlo<sup>&reg; </sup></strong>should be administered in patients whose blood pressure is not adequately controlled on monotherapy with Irbesartan or amlodipine or for continuation of therapy for patients receiving irbesartan and amlodipine as separate tablets. Dose should be determined on a case-by-case basis, based on patient response to therapy with the individual components and the desired antihypertensive response.</p><p>The maximum recommended dose with <strong>Gizamlo<sup>&reg;</sup></strong> is 300mg/10mg per day. Treatment should be adjusted based on blood pressure response.</p><p><em>Pediatric patients:</em> The safety and efficacy of Irbesartan/Amlodipine has not been established in this population.</p><p><em>Elderly patients and patients with impaired renal function:</em> In general, no dosage reduction is necessary in elderly patients or patients with impaired renal function (regardless of the degree of impairment).</p><p><em>Patients with impaired hepatic function:</em> As the medicinal product contains amlodipine, <strong>Gizamlo<sup>&reg;</sup></strong> should be administered with caution in these patients.</p><p>Medicinal product for oral administration.</p><p>&nbsp;</p><p><strong>SYMPTOMS AND TREATMENT OF OVERDOSE OR ACCIDENTAL INGESTION:</strong></p><p>Experience in adults exposed to doses of up to 900 mg/day irbesartan for 8 weeks revealed no toxicity. No specific information is available on the treatment of overdose with irbesartan. Available data for amlodipine suggest that overdose could result in excessive peripheral vasodilatation and possibly reflex tachycardia, Marked and probably prolonged systemic hypotension and shock with fatal outcome have been reported.</p><p>The patient should be closely monitored and symptomatic and supportive treatment administered. Suggested measures include gastric lavage. Administration of activated charcoal to healthy subjects immediately or up to two hours after ingestion of amlodipine 10 mg has been shown to significantly decrease amlodipine absorption.</p><p>As amlodipine is highly protein bound and irbesartan is not removed from the body by hemodialysis, hemodialysis does not appear to be useful. If massive overdose should occur, active cardiac and respiratory monitoring should be initiated.</p><p>Frequent blood pressure measurement is essential.</p><p>Clinically significant hypotension due to amlodipine overdose calls for active cardiovascular support including elevation of the extremities and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Because clinical trials are conducted under widely varying conditions, the incidence of adverse reaction observed in the clinical trials of one drug cannot be directly compared to that observed in the clinical trials of other drugs and may not reflect that observed in practice. Irbesartan has been evaluated for safety in clinical studies.</p><p>Adverse events in patients receiving irbesartan were generally mild and transient with no relationship to the dose administered.</p><p>&nbsp;</p><p>The incidence of adverse events was not related to age, gender or race.</p><p>&nbsp;</p><p>Adverse events that have been reported in clinical trials or postmarketing experience with irbesartan are categorized below according to system organ class and frequency (see Table 1).</p><p>The frequency of adverse events is defined using the following convention:</p><p>Very common: (&ge; 1/10); common: (&ge; 1/100 to &lt; 1/10); uncommon: (&ge; 1/1000 to &lt; 1/100); rare; (&ge; 1/10 000 to &lt; 1/1 000); very rare: (&lt; 1/10 000), unknown: no incidence data available.</p><p>Frequencies of adverse reactions from postmarketing experience are unknown, as these reactions are reported voluntarily from a population of uncertain size.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 1 &ndash; Adverse Events Reported in Irbesartan Clinical Trials or Postmarketing Reports</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common (a)</p></td><td style="vertical-align:top"><p>Uncommon (b)</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkalemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness, headache</p></td><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea/vomiting</p></td><td style="vertical-align:top"><p>Diarrhea, dyspepsia/heartburn</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice, elevated liver function tests, hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema, urticaria</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Impaired renal function including cases of renal failure in patients at risk</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sexual dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue, edema</p></td><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes all adverse events whether causal relationship to therapy is probable possible or unlikely, irrespective of incidence in the placebo-treated patients</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes all adverse events whether causal relationship to therapy is probable possible or unlikely, occurring with an incidence of 0.5% to &lt;1% and at similar or slightly increased incidence in irbesartan treated patients compared to placebo-treated patients (no statistically significant differences between the 2 treatment groups)</p><p>For Amlodipine:</p><p>Adverse events that have been reported in amlodipine trials are categorized below according to system organ class and frequency (see Table 2).</p><p>The frequency of adverse events is defined using the following convention:</p><p>Very common: (&ge; 1/10); common: (&ge; 1/100 to &lt; 1/10); uncommon: (&ge; 1/1000 to &lt; 1/100); rare; (&ge; 1/10 000 to &lt; 1/1 000); very rare: (&lt; 1/10 000), unknown: no incidence data available.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 2 &ndash; Adverse Events Reported in Amlodipine Clinical Trials</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reactions&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperglycemia &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia, mood changes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness, headache, somnolence</p></td><td style="vertical-align:top"><p>Hypoesthesia, paresthesia, tremor, taste perversion, syncope</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute myocardial infarction, arrhythmia, ventricular tachycardia and atrial &nbsp;fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea, rhinitis&nbsp;</p></td><td style="vertical-align:top"><p>Coughing</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, abdominal pain&nbsp;</p></td><td style="vertical-align:top"><p>Dyspepsia, vomiting, altered bowel habits, dry mouth</p></td><td style="vertical-align:top"><p>Pancreatitis, gastritis, gingival hyperplasia</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis, jaundice and elevated liver enzymes (in most cases consistent with cholestasis)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urticaria, pruritus, purpura, increased sweating, skin discoloration, alopecia&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema, erythema multiforme, urticaria</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia, muscle cramps, myalgia, back pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased urinary frequency, micturition disorder, nocturia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Impotence, gynecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue, edema</p></td><td style="vertical-align:top"><p>Chest pain, asthenia, general malaise, nonspecific pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight gain, weight loss</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>In clinical trials comparing the fixed-dose combination irbesartan/amlodipine to either irbesartan or amlodipine monotherapy, the types and incidences of treatment-emergent adverse events (TEAEs) possibly related to study treatment were similar to those observed earlier monotherapy clinical trials and postmarketing reports. The most frequently reported adverse event was peripheral edema, mainly associated with amlodipine (see table 3).</p><p>The following CIOMS frequency rating is used, when applicable:</p><p>Very common: &ge; 10 %; common: &ge; 1 and &lt; 10 %; uncommon: &ge; 0.1 % and &lt; 1%; rare; &ge; 0.01 % and &lt; 0.1 %; very rare: &lt; 0.01 %, unknown (cannot be estimated from available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table 3 &ndash; Treatment-Emergent Adverse Events Considered Possibly Related to Study Drug in Irbesartan/Amlodipine Clinical Studies.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Irbesartan monotherapy </strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Upper abdominal pain, nausea, tongue disorders</p></td><td style="vertical-align:top"><p>Diarrhea</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fall</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Amlodipine Monotherapy </strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Peripheral edema</p></td><td style="vertical-align:top"><p>Edema, facial edema</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Glossodynia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Contact dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hot flush</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Irbesartan/Amlodipine fixed dose combination </strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Peripheral edema, edema</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Sinus bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness, headache, somnolence</p></td><td style="vertical-align:top"><p>Paresthesia</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Postural hypotension</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Gingival swelling</p></td><td style="vertical-align:top"><p>Nausea, upper abdominal pain, constipation</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Proteinuria</p></td><td style="vertical-align:top"><p>Azotemia, hypercreatinemia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkalemia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Joint stiffness, arthralgia, myalgia</p></td></tr></tbody></table><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take this medicine after the expiry date which is printed on the outer pack. The expiry date refers.to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required.&nbsp; These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances of <strong>Gizamlo<sup>&reg;</sup></strong> are irbesartan and amlodipine (as amlodipine besilate). Each film coated tablet of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gizamlo<sup>&reg;</sup></strong><strong><sup> </sup></strong><strong>150mg/5mg </strong>contains 150 mg irbesartan and 5 mg amlodipine (as amlodipine besilate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gizamlo<sup>&reg; </sup></strong><strong>150mg/10mg </strong>contains 150 mg irbesartan and 10 mg amlodipine (as amlodipine besilate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gizamlo<sup>&reg;</sup></strong><strong><sup> </sup></strong><strong>300mg/5mg</strong> contains 300 mg irbesartan and 5 mg amlodipine (as amlodipine besilate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gizamlo<sup>&reg;</sup></strong><strong><sup> </sup></strong><strong>300mg/10mg</strong> contains 300 mg irbesartan and 10 mg amlodipine (as amlodipine besilate).</p><p>&nbsp;</p><p>The inactive ingredients are: Croscarmellose sodium, microcrystalline cellulose, hypromellose, colloidal anhydrous silica, magnesium stearate, polyethylene glycol and titanium dioxide. <strong>Gizamlo<sup>&reg; </sup></strong><strong>150mg/10mg </strong>contains red iron oxide (E172). <strong>Gizamlo<sup>&reg;</sup></strong> <strong>300mg/5mg </strong>contains yellow iron oxide (E172)<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gizamlo® 150mg/5mg film coated tablets are white oval – shaped film coated tablets coded (C178) on one side and plain on the other side. 
Gizamlo® 150mg/10mg film coated tablets are pink oval – shaped film coated tablets coded (C177) on one side and plain on the other side. 
Gizamlo® 300mg/5mg film coated tablets are yellow oval – shaped film coated tablets coded (C176) on one side and plain on the other side. 
Gizamlo® 300mg/10mg film coated tablets are white oval – shaped film coated tablets coded (C175) with mid-groove on one side and plain on the other side. 
Gizamlo® film coated tablets are packed in Aluminum blisters which are enclosed in a carton along with a leaflet. These are available in packs of 30 (3 blisters each containing 10 tablets) tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd.</p><p>Prince Hashem Bin Al-Hussein Street</p><p>Na&rsquo;ur &ndash; Amman &minus; Jordan</p><p>Tel. (+962 6) 57 27 132</p><p>Fax. (+962 6) 57 27 776</p><p>&nbsp;</p><p><strong>To report any side effects:</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jordan</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Contact marketing authorization holder</p></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966- 112038222, Ext 2317, 2356, 2340</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United Arab Emirates</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacovigilance and Medical Device Section</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug Department</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UAE Ministry of Health &amp; Prevention</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hotline: 80011111</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Email: pv@moh.gov.ae</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box: 1853 Dubai UAE</p></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudan</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; National Medicines and Poisons Board (NMPB)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Fax: + 249 183522263</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; E-mail: info@nmpb.gov.sd</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Website : www.nmpb.gov.sd</p></td></tr></tbody></table><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other countries</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>جزاملو</strong> على المادتين الفعالتين إربيزارتان وأملوديبين. تساعد هاتان المادتان في السيطرة على ضغط الدم المرتفع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي إربيزارتان إلى مجموعة من الأدوية تدعى مضادات مستقبلات الانجيوتنسين II. يتم انتاج انجيوتنسين II في الجسم ويرتبط بمستقبلات في الأوعية الدموية مما يسبب تضيقها. وبالتالي ينتج عن ذلك ارتفاع في ضغط الدم. يمنع إربيزارتان من ارتباط انجيوتنسين II بهذه المستقبلات مما يسبب ارتخاء الأوعية الدموية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي أملوديبين إلى مجموعة من الادوية تدعى &quot;مضادات قنوات الكالسيوم&quot;. يوقف أملوديبين دخول الكالسيوم إلى جدران الأوعية الدموية وبالتالي يمنع الأوعية الدموية من التضيق.</p><p dir="RTL">يستخدم <strong>جزاملو</strong> في علاج ارتفاع ضغط الدم في المرضى البالغين الذين لم يتم السيطرة على ضغط الدم لديهم بصورة كافية عند استخدام العلاج الأحادي من إربيزارتان أو أملوديبين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام </strong><strong>جزاملو</strong></p><p dir="RTL">يحتوي هذا <strong>جزاملو</strong> على المادتين الفعالتين إربيزارتان وأملوديبين، لذا فإنه يمنع إعطائه للمرضى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المصابين بحساسية تجاه أي من المادتين الفعالتين أو كلاها أو لأي من مكونات هذا الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المصابين بفرط الحساسية للدايهيدروبيريدينات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المصابين بصدمة قلبية ، تضيق أبهري ملحوظ سريرياً ، ذبحة صدرية غير مستقرة (باستثناء ذبحة برينزميتال)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمل والرضاعة</p><p dir="RTL">يمنع الاستخدام المتزامن <strong>ل</strong><strong>جزاملو</strong> مع المنتجات التي تحتوي على الأليسكيرين في المرضى الذين يعانون من مرض السكري أو القصور الكلوي المتوسط الى الشديد (معدل الترشيح الكبيبي (أقل من 60مل / دقيقة / 1.73 م 2)).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات </strong></p><p dir="RTL"><em><u>انخفاض ضغط الدم:</u></em><u> </u>المرضى ذوي حجم سوائل منخفض: الإربيزارتان يرتبط نادرا بحدوث انخفاض ضغط الدم لدى مرضى ضغط الدم المرتفع الذين لا يعانون من أي حالات مرضية أخرى. كما هو الحال مع مثبطات الإنزيم المحول للأنجيوتنسين ، يمكن أن يحدث انخفاض ضغط الدم عرضي لدى المرضى الذين يعانون من نقص الصوديوم / حجم السوائل والمرضى الذين يتلقون العلاج بمدرات البول بشكل مكثف و/أو الذين يتبعون حميات قليلة الملح، أو مرضى غسيل الكلى. يجب تصحيح حجم السوائل والصوديوم قبل بدء العلاج <strong>ب</strong><strong>جزاملو</strong> أو البدء بأقل جرعة ممكنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>معدلات </u></em><em><u>المرض والوفاة في الأجنة/حديثي الولادة:</u></em><u> </u>على الرغم من عدم وجود تجارب لاستخدام الإربيزارتان لدى النساء الحوامل ، إلا أن التعرض لمثبطات الإنزيم المحول للأنجيوتنسين أثناء الثلثين الثاني والثالث من الحمل قد تسبب في حدوث ضرر ووفاة الجنين. وبالتالي، كما هو الحال مع أي دواء يعمل مباشرة على نظام الرينين- أنجيوتنسين-ألدوستيرون ، ينبغي عدم استخدام <strong>جزاملو</strong> أثناء الحمل. إذا تم اكتشاف الحمل أثناء العلاج ، فيجب إيقاف <strong>جزاملو</strong> في أسرع وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>المرضى الذين يعانون من قصور القلب:</u></em><u> </u>ارتبط أملوديبين مع زيادة في الوذمة الرئوية في المرضى الذين يعانون من قصور القلب &nbsp;من القئة الثالثة والرابعة غير المرتبط بنقص التروية حسب التصنيف الوظيفي لجمعية القلب في نيويورك على الرغم من عدم وجود فرق ملحوظ في معدل جدوث تفاقم في قصور القلب مقارنة مع من تلقوا العلاج الغفل .</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><em><u>اعتلال الكبد:</u></em><u> </u>كما هو الحال مع مضادات الكالسيوم الأخرى ، يصبح عمر النصف لأملوديبين أطول في المرضى الذين يعانون من ضعف في وظائف الكبد ولم يتم تحديد توصيات بشأن الجرعات المناسبة لهذه الفئة من المرضى. لذلك يجب أن يستخدم مزيج <strong>جزاملو</strong> بحذر لدى هؤلاء المرضى.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><em><u>نوبة فرط ضغط الدم</u></em><u>: </u>لم تثبت مأمونية وفعالية مزيج إربيزارتان/أملوديبين في نوبات فرط ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>التثبيط المزدوج لنظام رينين أنجيوتنسين-ألدوستيرون عند الإستخدام المتزامن للأدوية المحتوية على الإليسكيرين :</u></em><u> </u>لا يوصى بالتثبيط المزدوج لنظام رينين-أنجيوتنسين-ألدوستيرون الناتج من استخدام مزيج إربيزارتان/أملوديبين مع الأليسكيرين حيث أنه يزيد من خطر انخفاض ضغط الدم، وفرط بوتاسيوم الدم، واعتلال وظيفة الكلى. لا ينبغي الاستخدام المتزامن لمزيج إربيزارتان/أملوديبين مع الأليسكيرين في المرضى الذين يعانون من السكري أو قصور وظائف الكلى (معدل الترشيح الكبيبي (أقل من 60مل / دقيقة / 1.73 م 2)).</p><p dir="RTL">نتيجة لتثبيط نظام رينين أنجيوتنسين-ألدوستيرون ، من المتوقع حدوث تغييرات في وظائف الكلى لدى الأفراد المعرضين. لدى المرضى الذين تعتمد وظائفهم الكلوية على نشاط نظام رينين أنجيوتنسين-ألدوستيرون (مرضى ارتفاع ضغط الدم يعانون من تضيق الشريان الكلوي في احدى الكلى أو كلاها ، أو المرضى الذين يعانون من قصور القلب الاحتقاني الشديد) ، فقد سبب استخدام الأدوية الأخرى التي تؤثر على هذا النظام قلة البول و/أو ارتفاع مركبات النيتروجين في الدم الذي يتفاقم مع الوقت و نادراً الفشل الكلوي الحاد و/أو الموت. لا يمكن استبعاد احتمال حدوث تأثير مماثل عند استخدام مضادات مستقبلات أنجيوتنسين II، بما في ذلك الإربيزارتان.</p><p dir="RTL"><em><u>&nbsp;</u></em></p><p dir="RTL"><em><u>الاستخدام من قبل كبار السن</u></em><u>:</u> في الدراسات السريرية التي أجريت على مرضى تلقوا إربيزارتان، لم يتم ملاحظة&nbsp; وجود فروقات في الفعالية أو المأمونية بين المرضى كبار السن (65 سنة أو أكثر) والمرضى الأصغر سنا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الاستخدام في الأطفال</em>: لم تثبت مأمونية وفعالية مزيج<strong> </strong>إربيزارتان/أملوديبين<strong> </strong>لدى المرضى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع غيره من الأدوية، الاعشاب أو المكملات الغذائية</strong></p><p dir="RTL"><em><u>مزيج إربيزارتان/أملوديبين:</u></em><em><u> </u></em>تشير الدراسات الحركية الدوائية إلى أنه لا يوجد تفاعل حركي دوائي بين إربيزارتان وأملوديبين إذا تم إعطاؤهما على انفراد أو معًا. لا توجد دراسات متاحة للتداخلات الدوائية لمزيج إربيزارتان/أملوديبين مع المنتجات الطبية الأخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><em><u>إربيزارتان</u></em>: بناءا على البيانات المخبرية، لا يرجح حدوث تفاعلات مع الأدوية التي يعتمد استقلابها على انزيمات سيتوكروم P450 التالية: CYP1A1، CYP1A2، CYP2A6، CYP2B6، CYP2D6، CYP2E1 أو CYP3A4. يتم استقلاب الإربيزارتان بشكل أساسي عن طريق إنزيم CYP2C9 ، ومع ذلك ، لم يلاحظ خلال دراسات التداخلات السريرية أي تفاعلات دوائية كبيرة عند استخدام الإربيزارتان بالتزامن مع الوارفارين (الذي يتم استقلابه بواسطة انزيم CYP2C9). لا تتأثر الخصائص الحركية الدوائية لإربيزارتان عند تناوله بالتزامن مع نيفيديبين أو هيدروكلوروثيازيد. لا يؤثر الإربيزارتان على الخصائص الحركية الدوائية لسيمفاستاتين (الذي يتم استقلابه بواسطة انزيم CYP3A4) أو الديجوكسين (ركيزة لناقل تدفق الجليكوبروتين P). بناءً على الخبرة المكتسبة من استخدام الأدوية الأخرى التي تؤثر على نظام الرينين - أنجيوتنسين ، فإن الاستخدام المتزامن لمدرات البول الموفرة للبوتاسيوم أو مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم قد يزيد من مستويات البوتاسيوم في الدم.</p><p dir="RTL">يمنع الاستخدام المتزامن <strong>ل</strong><strong>جزاملو</strong> مع المنتجات التي تحتوي على الأليسكيرين في المرضى الذين يعانون من مرض السكري أو القصور الكلوي المتوسط إلى الشديد (معدل الترشيح الكبيبي (أقل من 60مل / دقيقة / 1.73 م 2))، ولا يوصى بهذا الاستخدام في فئات أخرى من المرضى. من الممكن أن يؤدي الاستخدام المتزامن لإربيزارتان مع مضادات الالتهاب غير الستيرويدية بما فيها مثبطات انزيم الأكسدة الحلقي 2 الانتقائية أو أي مثبط لمستقبل انجيوتنسين II بما في ذلك الاربيزارتان في كبار السن، مرضى انخفاض حجم السوائل (يشمل ذلك المرضى الذين يتلقون علاج المدرات البولية) أو مرضى القصور الكلوي إلى تراجع في الوظيفة الكلوية مع احتمال حدوث فشل كلوي حاد. تكون هذه الأعراض عادة قابلة للشفاء. يجب التحقق من وظائف الكلى بشكل دوري في المرضى الذين يتلقون إربيزارتان مع مضادات الالتهاب غير الستيرويدية كعلاج عرضي. قد تقلل مضادات الالتهاب غير الستيرويدية بما فيها مثبطات انزيم الأكسدة الحلقي 2 الانتقائية من التأثير الخافض للضغط لمثبطات مستقبلات انجيوتنسين II بما فيها إربيزارتان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em><u>أملوديبين: </u></em>تم تناول الأملوديبين &nbsp;بأمان بالتزامن مع مدرات البول الثيازيدية وحاصرات بيتا وحاصرات ألفا ومثبطات الإنزيم المحول للأنجيوتنسين والنترات طويلة المفعول و الغليسيريل ثلاثي النترات الذي يتم اعطاؤه تحت اللسان ومضادات الالتهاب غير الستيرويدية والمضادات الحيوية وخافضات سكر الدم المعطاة عن طريق الفم.</p><p dir="RTL">تشير الدراسات الدوائية على أنسجة الانسان انه ليس لأملوديبين أي تأثير على ارتباط الأدوية التالية بالبروتين (ديجوكسين، فينيتوين ، وارفارين أو إندوميثاسين).</p><p dir="RTL">السيميتيدين: لم تتأثر الخصائص الحركية الدوائية للأملوديبين عند استخدامه بالتزامن مع السيميتيدين.</p><p dir="RTL">عصير الجريب فروت: لم يكن هناك أي تاثير ملحوظ على الخصائص الحركية الدوائية لأملوديبين عند تزامن تناول جرعة منفردة مقدارها 10 ملغم منه عن طريق الفم مع &nbsp;240 مل من عصير الجريب فروت.</p><p dir="RTL">مضادات الحموضة المحتوية على الألمنيوم/المغنيسيوم: لم يكن هناك أي تاثير ملحوظ على الخصائص الحركية الدوائية لأملوديبين عند تزامن تناول جرعه منفرده&nbsp; منه مع مضادات الحموضة المحتوية على الألمنيوم أو المغنيسيوم.</p><p dir="RTL">سلدينافيل: عندما تم استخدام أملوديبين و سلدينافيل بالتزامن ، كان لكل منهما تأثير مستقل في خفض ضغط الدم.</p><p dir="RTL">أتورفاستاتين: لم ينتج عن التزامن في إعطاء جرعات متعددة من 10 ملغم من أملوديبين مع 80 ملغم من أتورفاستاتين أي تغيير كبير على مؤشرات الحركية الدوائية في حالة الثبات لأتورفاستاتين.</p><p dir="RTL">ديجوكسين: لم يغير التناول المتزامن لأملوديبين مع ديجوكسين من مستويات الديجوكسين في المصل أو طرحه الكلوي في الأصحاء.</p><p dir="RTL">وارفارين: لم يتغير تأثير الوارفارين على زمن البروثرومبين عند اعطائه بالتزامن مع أملوديبين.</p><p dir="RTL">سيكلوسبورين: تشير الدراسات الحركية لسيكلوسبورين أنه لا يوجد تأثير كبير للأملوديبين على خصائصه الحركية الدوائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إربيزارتان: </strong></p><p dir="RTL">لم يتم رصد أي أدلة تشير إلى أن إربيزارتان مسبب للسرطان عند إعطائه بجرعات تصل إلى 500/1000 ملغم/كغم/يوم في الجرذان (الذكور/الإناث، على التوالي) و1000 ملغم/كغم/يوم في الفئران لمدة سنتين. يكون مقدار التعرض الجهازي الذي توفره هذه الجرعات 4-25 ضعف (في الجرذان) و4-6 أضعاف (في الفئران) مقدار التعرض الذي يكون في الانسان الذي يتلقى 300 ملغم/يوم. كما لم يتسبب إربيزارتان بحدوث طفرات في مجموعة من الاختبارات المعملية تم إجراؤها (إختبار أميس الميكروبي، إختبار ترميم الحمض النووي على الخلايا الكبدية في الجرذان، اختبار الطفرة الجينية على خلية V79 للثديات). سجل إربيزارتان نتيجة سلبية تجاه العديد من الاختبارات التي تثير الانحراف الكروموسومي (اختبار الخلية الليمفاوية البشرية المخبري، الدراسة المخبرية للنواة الميكروية في الفئران). لم تتأثر الخصوبة وأداء الجهاز التناسلي في الدراسات التي أجريت على ذكور وإناث الجرذان، حتى على الجرعات التي تسبب بعض السمية (تصل إلى 650ملغم/كغم/يوم).&nbsp;</p><p dir="RTL">لم تتم ملاحظة أي تأثيرات كبيرة على أعداد الأجسام الصفراء، الغرسات أو الأجنة الحية.</p><p dir="RTL">لم يكن هناك أي تأثير للإربيزارتان على بقاء النسل، نموه أو تكاثره.</p><p dir="RTL">تم رصد آثار سمية عابرة (زيادة تجويف الحوض الكلوي، تميه الحالب أو وذمة تحت الجلد) لأجنة الجرذان على جرعات مقدارها 50 ملغم/كغم/يوم فأكثر، التي ظهرت بعد الولادة. كما تم رصد حالات موت، إجهاض وولادة مبكرة في إناث الأرانب على جرعات مقدارها&nbsp; 30 ملغم/كغم/يوم.</p><p dir="RTL">لم يتم رصد أي تشوهات جنينية أخرى في الجرذان أو الأرانب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>أملوديبين: </u></strong></p><p dir="RTL">السرطنة: &nbsp;لم يظهر أي دليل على السرطنة في الجرذان والفئران التي عولجت بالأملوديبين في النظام الغذائي لمدة عامين، بتراكيز توفر جرعة يومية مقدارها 0.5، 1.25 و 2.5 ملغم/كغم/يوم. كانت الجرعة القصوى (التي تشبه الجرعة القصوى الموصى بها في الانسان ومقدارها 10 ملغم محسوبة بـ ملغم/م2 في الفئران، وحوالي ضعف* الجرعة القصوى في الجرذان) قريبة من الجرعة القصوى التي يستطيع تحملها الفئران دون الجرذان.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">التشوهات الجنينية: أظهرت دراسات التشوهات الجنينية أنه لا تأثير متعلق بالأملوديبين سواء أكان ذلك على مستوى الجينات أو الكروموسومات.</p><p dir="RTL">العقم: لم يكن هناك أي تأثير على خصوبة الجرذان التي عولجت بالأملوديبين بجرعات تصل إلى 10 ملغم/كغم/يوم (8 أضعاف * الجرعة القصوى الموصى بها في الانسان والتي مقدارها 10 ملغم محسوبة بـ ملغم/م2).</p><p dir="RTL">*(إعتبارا أن وزن المريض 50 كغم)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول </strong><strong>جزاملو</strong><strong> </strong><strong>مع الطعام أو الشراب </strong></p><p dir="RTL">من الممكن أخذ <strong>جزاملو</strong> مع أو بدون طعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة:</strong></p><p dir="RTL"><em><u>الحمل: </u></em>لا توجد دراسات كافية ومسيطر عليها بشكل جيد في النساء الحوامل. يمنع استخدام مزيج&nbsp; إربيزارتان/أملوديبين أثناء الحمل. كما يمنع استخدام <strong>جزاملو </strong>في النساء في سن الإنجاب ما لم يتم استخدام وسائل منع حمل فعالة.</p><p dir="RTL">في حال تم اكتشاف الحمل أثناء العلاج <strong>ب</strong><strong>جزاملو،</strong> يجب وقف العلاج في أقرب وقت ممكن.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em><u>الأمهات المرضعات: </u></em>يمنع تناول <strong>جزاملو</strong> أثناء الرضاعة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إلتزم بتناول <strong>جزاملو</strong> تماما كما أرشدك الطبيب. تحقق من الطبيب أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">تكون جرعة المداومة والجرعة الإبتدائية من&nbsp; <strong>جزاملو</strong> عادة &nbsp;قرص واحد في اليوم.</p><p dir="RTL">يمكن تناول <strong>جزاملو</strong> مع أو بدون طعام.</p><p dir="RTL">يمكن تناول <strong>جزاملو</strong> في المرضى الذين لا يتم السيطرة على ضغط الدم لديهم بشكل كافي باستخدام العلاج الأحادي من إربيزارتان أو أملوديبين أو لمواصلة العلاج للمرضى الذين يتلقون إربيزارتان وأملوديبين كأقراص منفصلة. يجب أن يتم تحديد الجرعة لكل حالة على حدى، بناءاً على الاستجابة الفردية للمرضى والاستجابة المطلوبة لخفض ضغط الدم.</p><p dir="RTL">الجرعة القصوى الموصى بها من <strong>جزاملو</strong> هي 300 ملغم / 10 ملغم يوميًا. يجب ضبط العلاج بناءا على استجابة ضغط الدم.</p><p dir="RTL"><em>المرضى الأطفال:</em> لم تثبت مأمونية وفعالية مزيج&nbsp; إربيزارتان / أملوديبين في هذه الفئة من المرضى.</p><p dir="RTL"><em>المرضى كبار السن والمرضى الذين يعانون من ضعف وظائف الكلى:</em> بشكل عام ، لا يلزم تخفيض الجرعة في المرضى المسنين أو المرضى الذين يعانون من ضعف وظائف الكلى (بغض النظر عن درجة الاعتلال).</p><p dir="RTL"><em>المرضى الذين يعانون من اختلال وظائف الكبد:</em> نظرًا لوجود أملوديبين في هذا الدواء، يجب إعطاء <strong>جزاملو</strong> بحذر في هذه الفئة من المرضى.</p><p dir="RTL">يؤخذ هذ الدواء عن طريق الفم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض التي تحدث من الجرعة الزائدة أو تناول الدواء عن طريق الخطأ وعلاجها:</strong></p><p dir="RTL">أظهرت الخبرة بإربيزارتان عدم وجود سمية عند التعرض لجرعات تصل إلى 900 ملغم / يوم من قبل البالغين لمدة 8 أسابيع. لا توجد معلومات محددة عن علاج الجرعة الزائدة من إربيزارتان. تشير البيانات المتاحة لأملوديبين أن الجرعة الزائدة منه قد تؤدي إلى توسع الأوعية المحيطية المفرط وتسارع دقات القلب الانعكاسي. وقد تم الإبلاغ عن انخفاض ملحوظ لضغط الدم الجهازي وغالباً لفترة طويلة بما في ذلك صدمة مع نتائج مميتة.</p><p dir="RTL">يجب مراقبة المريض عن كثب ، ويجب أن يكون العلاج داعمًا وموجه للأعراض. تشمل التدابير المقترحة غسيل المعدة. تبين أن تناول الفحم المنشط على الفور أو حتى ساعتين بعد تناول أملوديبين 10 ملغم يقلل من امتصاص أملوديبين بشكل ملحوظ.</p><p dir="RTL">بما أن أملوديبين شديد الارتباط بالبروتين والإربيزارتان لا تتم إزالته من الجسم عن طريق غسيل الكلى فمن غير المرجح أن يكون غسيل الكلى مفيدًا في هذه الحالة. في حال كانت الجرعة الزائدة كبيرة ، يجب البدء بمراقبة دقيقة للقلب والجهاز التنفسي.</p><p dir="RTL">يعد قياس ضغط الدم بشكل متكرر ضرورياً.</p><p dir="RTL">إن انخفاض ضغط الدم بشكل ملحوظ &nbsp;بسبب الجرعة الزائدة من أملوديبين يستدعي الدعم المكثف للقلب والأوعية الدموية بما في ذلك رفع الأطراف والانتباه إلى حجم &nbsp;سوائل الجسم وإدرار البول. قد تكون قابضات الأوعية الدموية مفيدة في استعادة وضع الأوعية الدموية وضغط الدم ، بشرط ألا يكون هناك أي موانع لاستخدامها. قد تكون غلوكونات الكالسيوم المعطاة عن طريق الوريد مفيدة في عكس آثار تثبيط قناة الكالسيوم.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى تتعلق باستخدام الدواء، فاستشر الطبيب أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم إجراء التجارب السريرية تحت العديد من الظروف المختلفة، لذا فإن تكرار الأعراض الجانبية التي يتم رصدها من دواء معين لا يمكن مقارنتها بشكل مباشر مع تلك التي يتم رصدها في التجارب السريرية مع أدوية أخرى كما &nbsp;قد لا تنعكس على ما يتم ملاحظته مع الممارسة. تم إختبار مأمونية الإربيزارتان في التجارب السريرية. كانت الأعراض الجانبية في المرضى الذين يتلقون إربيزارتان خفيفة وعابرة بشكل عام وغير مرتبطة بالجرعة.</p><p dir="RTL">لم يكن حدوث الأعراض الجانبية مرتبطًا بالعمر أو الجنس أو العرق.</p><p dir="RTL">يتم تصنيف الأعراض الجانبية التي تم الإبلاغ في الدراسات السريرية أو من الخبرة بعد التسويق لإربيزارتان وفقًا لفئة الجهاز وتكرارها (انظر الجدول1)</p><p dir="RTL">&nbsp;يتم تعريف تكرار الأعراض الجانبية كالتالي:</p><p dir="RTL">&nbsp;شائع جدا (&ge; 1/10) ؛ شائع (&ge; 1/100 إلى &lt; 1/10) ؛ غير شائع &nbsp;(&ge;1/1000 إلى &lt; 1/100) ؛ نادر (&ge; 1/10000 إلى &lt; 1/1000)&nbsp; ؛ نادر جدًا (&lt;1/10000) ؛ غير معروف: لا توجد بيانات متاحة.</p><p dir="RTL">غير معروف تكرار الأعراض الجانبية التي رصدت من الخبرة بعد التسويق حيث أنه تم رصد هذه الأعراض بصورة تلقائية من بين فئات غير معروفة العدد.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p dir="RTL">الجدول 1 &ndash; الأعراض الجانبية مع إربيزارتان التي رصدت من الدراسات السريرية أو من الخبرة بعد التسويق</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">شائع (أ)</p></td><td style="vertical-align:top"><p dir="RTL">غير شائع (ب)</p></td><td style="vertical-align:top"><p dir="RTL">غير معروف</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز المناعي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">تفاعلات فرط الحساسية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأيض و التغذية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ارتفاع بوتاسيوم الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز العصبي</p></td><td style="vertical-align:top"><p dir="RTL">دوخة وصداع</p></td><td style="vertical-align:top"><p dir="RTL">دوخة عند الوقوف</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات القلب</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">تسارع دقات القلب</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التنفسي والصدر والمنصف</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">سعال</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز الهضمي</p></td><td style="vertical-align:top"><p dir="RTL">غثيان/تقيؤ</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">إسهال ، وعسر الهضم / حرقة المعدة</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الكبد والقناة الصفراوية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">يرقان، ارتفاع في نتائج اختبارات وظائف الكبد، التهاب الكبد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجلد والانسجة اللينة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">وذمة وعائية، شرى</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات عضلية هيكلية واضطرابات الأنسجة الضامة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ألم العضلات</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الكلى والمسالك البولية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ضعف وظائف الكلى بما في ذلك حالات من الفشل الكلوي في المرضى المعرضين لهذا الخطر</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التناسلي و الثدي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">اضطرابات جنسية</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات العامة والموضعية</p></td><td style="vertical-align:top"><p dir="RTL">تعب ، وذمة</p></td><td style="vertical-align:top"><p dir="RTL">ألم في الصدر</p></td><td style="vertical-align:top"><p dir="RTL">وهن</p><p dir="RTL">&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p dir="RTL">أ. تشمل جميع الأعراض الجانبية ، التي قد يكون سببها مرتبطا بالعلاج، أو غير مرجح&nbsp; الارتباط بالعلاج مهما كان تكرار هذه الأعراض في المرضى الذين تلقوا العلاج الغفل.</p><p dir="RTL">ب. تشمل جميع الأعراض الجانبية ، التي قد يكون سببها مرتبطا بالعلاج، أو غير مرجح&nbsp; الارتباط بالعلاج، والتي تحدث بتكرار يتراوح من 0.5٪ إلى &lt;1٪ وفي تكرار مماثل أو بزيادة طفيفة في المرضى الذين تلقوا إربيزارتان مقارنة بالمرضى الذين تلقوا العلاج الغفل (لم يكن أي منهم اختلاف إحصائي ملحوظ &nbsp;بين مجموعتي العلاج).</p><p dir="RTL">أملوديبين</p><p dir="RTL">يتم تصنيف الأعراض الجانبية التي تم الإبلاغ عنها مع أملوديبين أدناه وفقًا لفئة الجهاز والتكرار (انظر الجدول 2).</p><p dir="RTL">يتم تعريف تكرار الأعراض الجانبية بناءا على المصطلحات التالية:&nbsp;</p><p dir="RTL">شائع جدا (&ge; 1/10) ؛ شائع (&ge; 1/100 إلى &lt; 1/10) ؛ غير شائع &nbsp;(&ge;1/1000 إلى &lt; 1/100) ؛ نادر (&ge; 1/10000 إلى &lt; 1/1000)&nbsp; ؛ نادر جدًا (&lt;1/10000) ؛ غير معروف: لا توجد بيانات متاحة.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p dir="RTL">الجدول 2 &ndash; الأعراض الجانبية مع أملوديبين التي رصدت من الدراسات السريرية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">غير شائع</p></td><td style="vertical-align:top"><p dir="RTL">نادر جدا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الدم والجهاز اللمفاوي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">نقص الصفائح الدموية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز المناعي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">تفاعلات الحساسية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأيض والتغذية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ارتفاع سكر الدم</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات نفسية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">أرق ، تغير المزاج</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز العصبي</p></td><td style="vertical-align:top"><p dir="RTL">دوخة ، وصداع ، ونعاس</p></td><td style="vertical-align:top"><p dir="RTL">نقص الحس ، تنمل، رجفة، اضطراب الذوق، إغماء</p></td><td style="vertical-align:top"><p dir="RTL">الاعتلال العصبي المحيطي</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات العين</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">اضطرابات بصرية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأذن والدهليز</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">طنين الأذن</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات القلب</p></td><td style="vertical-align:top"><p dir="RTL">الخفقان</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">احتشاء عضلة القلب، اضطراب نظم القلب، تسارع نظم القلب البطيني والرجفان الأذيني</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأوعية الدموية</p></td><td style="vertical-align:top"><p dir="RTL">تورد</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض ضغط الدم</p></td><td style="vertical-align:top"><p dir="RTL">التهاب الأوعية الدموية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهازالتنفسي والصدر والمنصف</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">صعوبة التنفس، التهاب الأنف</p></td><td style="vertical-align:top"><p dir="RTL">سعال</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهازالهضمي</p></td><td style="vertical-align:top"><p dir="RTL">غثيان، ألم في البطن</p></td><td style="vertical-align:top"><p dir="RTL">عسر الهضم ، تقيؤ، تغير في حركة الأمعاء، جفاف الفم</p></td><td style="vertical-align:top"><p dir="RTL">التهاب البنكرياس، التهاب المعدة، تضخم اللثة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الكبد والقناة الصفراوية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">التهاب الكبد، واليرقان، وارتفاع انزيمات الكبد (يرافقها في معظم الحالات ركود الصفراء)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجلد والأنسجة تحت الجلد</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">شرى، حكة، فرفرية، زيادة التعرق ، تلون الجلد، صلع</p></td><td style="vertical-align:top"><p dir="RTL">وذمة وعائية، حمامي متعددة الأشكال، شرى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات عضلية هيكلية واضطرابات الأنسجة الضامة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">آلام المفاصل وتشنجات العضلات وألم عضلي وآلام الظهر</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الكلى والمسالك البولية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زيادة التبول واضطراب التبول والتبول الليلي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التناسلي والثدي</p></td><td style="vertical-align:top"><p dir="RTL">العجز الجنسي، تضخم الثدي عند الرجال</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات العامة والموضعية</p></td><td style="vertical-align:top"><p dir="RTL">تعب، وذمة</p></td><td style="vertical-align:top"><p dir="RTL">ألم في الصدر، الوهن، والشعور بالضيق، ألم غير محدد</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الفحوص المخبرية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">زيادة الوزن، نقصان الوزن</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p dir="RTL">عند مقارنة تركيبة المزيج الثابت من إربيزارتان/أملوديبين بالعلاج الأحادي باستخدام الإربيزارتان أو لأملوديبين كل على حدى، كانت أنواع وتكرار الأعراض الجانبية المحتملة من المزيج مماثلة لتلك التي لوحظت سابقاً في العلاج الأحادي من خلال الدراسات السريرية وتقارير ما بعد التسويق. الأعراض الجانبية الأكثر شيوعًا هي الوذمة المحيطية، وترتبط بشكل رئيسي مع أملوديبين (انظر الجدول 3)</p><p dir="RTL">يتم استخدام تصنيف تكرار &nbsp;مجلس المنظمات الدولية للعلوم الطبية التالي، عند الحاجة:</p><p dir="RTL">شائع جدا (&ge;1/10%)، شائع (&ge;1 و &lt;10%)، غير شائع (&ge;0.1 و &lt;1%)، نادر (&ge;0.01 و˃0.1%)، نادر جداً (&lt;0.01%) غير معروفة: (لا يمكن تقديرها من خلال البيانات المتوفرة).</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p dir="RTL">الجدول 3 &ndash; الأعراض الجانبية المحتمل ارتباطها من مزيج إربيزارتان/أملوديبين في الدراسات السريرية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">شائع</p></td><td style="vertical-align:top"><p dir="RTL">غير شائع</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>العلاج الأحادي بالإربيزارتان </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات العامة والموضعية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">تعب</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأذن والدهليز</p></td><td style="vertical-align:top"><p dir="RTL">دوار</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز العصبي</p></td><td style="vertical-align:top"><p dir="RTL">دوخة</p></td><td style="vertical-align:top"><p dir="RTL">صداع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز الهضمي</p></td><td style="vertical-align:top"><p dir="RTL">ألم في أعلى البطن، غثيان، اضطرابات اللسان</p></td><td style="vertical-align:top"><p dir="RTL">إسهال</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجلد والأنسجة تحت الجلد</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">صلع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الإصابة والتسمم والمضاعفات الإجرائية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">سقوط</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>العلاج الأحادي بالأملوديبين </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات العامة والموضعية</p></td><td style="vertical-align:top"><p dir="RTL">وذمة محيطية</p></td><td style="vertical-align:top"><p dir="RTL">وذمة، وذمة الوجه</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأذن والدهليز</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">دوار</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز الهضمي</p></td><td style="vertical-align:top"><p dir="RTL">متلازمة الفم الحارق</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز العصبي</p></td><td style="vertical-align:top"><p dir="RTL">دوخة</p></td><td style="vertical-align:top"><p dir="RTL">صداع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التنفسي والصدر والمنصف</p></td><td style="vertical-align:top"><p dir="RTL">سعال</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجلد والأنسجة تحت الجلد</p></td><td style="vertical-align:top"><p dir="RTL">التهاب الجلد التماسي</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأوعية الدموية</p></td><td style="vertical-align:top"><p dir="RTL">هبات حرارة</p></td><td style="vertical-align:top"><p dir="RTL">تورد</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p dir="RTL"><strong>المزيج الثابت بإربيزارتان/أملوديبين </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الاضطرابات العامة وموضعية</p></td><td style="vertical-align:top"><p dir="RTL">وذمة محيطية، وذمة</p></td><td style="vertical-align:top"><p dir="RTL">وهن</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأذن والدهليز</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">دوار</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات القلب</p></td><td style="vertical-align:top"><p dir="RTL">خفقان</p></td><td style="vertical-align:top"><p dir="RTL">بطء القلب الجيبي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز العصبي</p></td><td style="vertical-align:top"><p dir="RTL">دوخة، صداع ، نعاس</p></td><td style="vertical-align:top"><p dir="RTL">تنميل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التناسلي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ضعف الانتصاب</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز التنفسي والصدر والمنصف</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">سعال</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأوعية الدموية</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض ضغط الدم عند الوقوف</p></td><td style="vertical-align:top"><p dir="RTL">انخفاض ضغط الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الجهاز الهضمي</p></td><td style="vertical-align:top"><p dir="RTL">تورم اللثة</p></td><td style="vertical-align:top"><p dir="RTL">غثيان، آلام أعلى البطن، إمساك</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الكلى والمسالك البولية</p></td><td style="vertical-align:top"><p dir="RTL">بيلة بروتينية</p></td><td style="vertical-align:top"><p dir="RTL">ارتفاع مركبات النيتروجين في الدم، ارتفاع كرياتين الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات الأيض والتغذية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">ارتفاع بوتاسيوم الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اضطرابات عضلية هيكلية واضطرابات النسيج الضام</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">تصلب المفاصل، ألم المفاصل، ألم العضلات</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">إذا أصبت بأي عرض جانبي، أخبر الطبيب أو الصيدلي. يتضمن ذلك أي أعراض جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول أيدي الأطفال نظرهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ على درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ الإنتهاء المذكور على العبوة . يدل تاريخ الإنتهاء على اخر يوم من الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في المياه العادمة أو النفايات المنزلية. اسأل الصيدلي حول الطريقة السليمة للتخلص من الادوية التي لم تعد بحاجة اليها. سيساعد هذا في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة في <strong>جزاملو</strong> هي الإربيزارتان والأملوديبين (على هيئة بيسيلات الأملوديبين). يحتوي كل قرص مغلف من:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>جزاملو&nbsp; 150ملغم/5ملغم</strong> على 150 ملغم إربيزارتان و5 ملغم أملوديبين (على هيئة بيسيلات الأملوديبين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>جزاملو 150ملغم/10ملغم</strong> على 150 ملغم إربيزارتان و10 ملغم أملوديبين (على هيئة بيسيلات الأملوديبين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>جزاملو 300 ملغم/5ملغم</strong> على 300 ملغم إربيزارتان و5 ملغم أملوديبين (على هيئة بيسيلات الأملوديبين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>جزاملو 300 ملغم/10ملغم</strong> على 300 ملغم إربيزارتان و10 ملغم أملوديبين (على هيئة بيسيلات الأملوديبين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد غير الفعالة: كروس كارميلوس الصوديوم، سليلوز دقيق البلورية، هيبروميلوز، سيليكا غروية لامائية، ستيارات المغنيسيوم، متعدد إيثيلين جليكول وثاني أكسيد التيتانيوم. يحتوي <strong>جزاملو</strong><strong> 150ملغم/10ملغم</strong> على لون أحمر(E172). يحتوي <strong>جزاملو</strong><strong> 300ملغم/5ملغم</strong> على لون أصفر(E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>الشكل</strong><strong> </strong><strong>الصيدلاني</strong><strong> </strong><strong>ل</strong><strong>جزاملو</strong><strong> </strong><strong>ووصفه</strong><strong> </strong><strong>وحجم</strong><strong> </strong><strong>عبوته </strong></p><p dir="RTL"><strong>أقراص </strong><strong>جزاملو</strong><strong> </strong><strong>150ملغم/5ملغم المغلفة </strong>هي أقراص بيضاء اللون بيضاوية الشكل مرمزة بـ(C178) &nbsp;&nbsp;من جهة وملساء من الجهة الأخرى.</p><p dir="RTL"><strong>أقراص </strong><strong>جزاملو</strong><strong> </strong><strong>150ملغم/10ملغم المغلفة </strong>هي أقراص وردية اللون بيضاوية الشكل مرمزة بـ (C177) من جهة وملساء من الجهة الأخرى.</p><p dir="RTL"><strong>أقراص </strong><strong>جزاملو</strong><strong> </strong><strong>300ملغم/5ملغم المغلفة </strong>هي أقراص صفراء اللون بيضاوية الشكل مرمزة بـ(C176) &nbsp;من جهة وملساء من الجهة الأخرى.</p><p dir="RTL"><strong>أقراص </strong><strong>جزاملو</strong><strong> </strong><strong>300ملغم/10ملغم المغلفة </strong>هي أقراص بيضاء اللون بيضاوية الشكل مرمزة بـ(C175) &nbsp;مع قطع عرضي من جهة وملساء من الجهة الأخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تغلف<strong> أقراص </strong><strong>جزاملو</strong> في أشرطة من الألمنيوم تعبأ في عبوات كرتونية مع نشرة معلومات المريض. تتوفر في عبوات مكونة من 30 قرص (3 أشرطة يحتوي كل منها على 10 أقراص).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة دارالدواء للتنمية والإستثمار المساهمة المحدودة</p><p dir="RTL">شارع الأمير هاشم بن الحسين</p><p dir="RTL">ناعور&ndash; عمان &ndash; الأردن</p><p dir="RTL">هاتف. 132 27 57 (6 962 +)</p><p dir="RTL">فاكس.776 27 57 (6 962 +)</p><p dir="RTL">&nbsp;</p><p><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الأردن </strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li dir="RTL">مؤسسة الغداء و الدواء الأردنية :</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف : 5632000-06</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني : www.jfda.jo&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبر التطبيق : Jordan FDA</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإبلاغ الورقي : Yellow card</p></td></tr></tbody></table><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية </strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><ul><li dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 112057662 966 +</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الرقم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; 112038222 966 +، فرعي: 2317-2356-2340</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الرقم الموحد 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني www.sfda.gov.sa/npc :</p></td></tr></tbody></table><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الإمارات العربية المتحدة</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قسم اليقظة الدوائية والوسائل الطبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدارة الدواء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزارة الصحة ووقاية المجتمع</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخط الساخن : ٨٠٠١١١١١</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايميل : pv@moh.gov.ae</p><p dir="RTL">&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صندوق بريد: ١٨٥٣ دبي الامارات العربية المتحدة</p></td></tr></tbody></table><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>السودان </strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المجلس القومي للأدوية والسموم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 183522263 249+</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: info@nmpb.gov.sd</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.nmpb.gov.sd</p></td></tr></tbody></table><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الدول الأخرى </strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gizamlo® 150 mg /5 mg Film coated tablets 
Gizamlo® 150 mg /10 mg Film coated tablets 
Gizamlo® 300 mg /5 mg Film coated tablets 
Gizamlo® 300 mg /10 mg Film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gizamlo® 150 mg /5 mg film-coated tablets: Each tablet contains 150 mg irbesartan and 5 mg amlodipine (as amlodipine besilate).
Gizamlo® 150 mg /10 mg film-coated tablets: Each tablet contains 150 mg irbesartan and 10 mg amlodipine (as amlodipine besilate).
Gizamlo® 300 mg /5 mg film-coated tablets: Each tablet contains 300 mg irbesartan and 5 mg amlodipine (as amlodipine besilate).
Gizamlo® 300 mg /10 mg film-coated tablets: Each tablet contains 300 mg irbesartan and 10 mg amlodipine (as amlodipine besilate).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablets
Gizamlo® 150mg/5mg film coated tablets are white oval – shaped film coated tablets coded (C178) on one side and plain on the other side.
Gizamlo® 150mg/10mg film coated tablets are pink oval – shaped film coated tablets coded (C177) on one side and plain on the other side.
Gizamlo® 300mg/5mg film coated tablets are yellow oval – shaped film coated tablets coded (C176) on one side and plain on the other side.
Gizamlo® 300mg/10mg film coated tablets are white oval – shaped film coated tablets coded (C175) with a mid-groove on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.</p><p><strong>Gizamlo</strong><strong>&reg; </strong>is indicated in patients whose blood pressure is not adequately controlled on irbesartan or amlodipine monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The usual initial and maintenance dose of <strong>Gizamlo</strong><strong>&reg; </strong>is one tablet per day.</p><p><strong>Gizamlo</strong><strong>&reg; </strong>can be administered with or without food.</p><p><strong>Gizamlo</strong><strong>&reg; </strong>should be administered in patients whose blood pressure is not adequately controlled on monotherapy with irbesartan or amlodipine or for continuation of therapy for patients receiving irbesartan and amlodipine as separate tablets. Dose should be individualized based on response to therapy with individual components and antihypertensive response required. The maximum recommended dose with <strong>Gizamlo</strong><strong>&reg; </strong>is 300 mg/10 mg per day.</p><p>Therapy should be adjusted according to blood pressure response.</p><p><em>Pediatric patients: </em>the safety and efficacy of Irbesartan/Amlodipine combination has not been established.</p><p><em>Elderly patients and patients with impaired renal function: </em>in general, no dosage reduction is necessary in elderly patients or patients with impaired renal function (regardless of degree).</p><p><em>Patients with impaired hepatic function: </em>due to the presence of amlodipine, <strong>Gizamlo</strong><strong>&reg;</strong> should be administered with caution. For oral administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Due to the presence of both Irbesartan and Amlodipine, Gizamlo® is contraindicated in:
-	Hypersensitivity to either or both of the active substances or to any of the formulation components.
-	Hypersensitivity to dihydropyridines
-	Cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal's angina)
-	Pregnancy and lactation
-	The concomitant use of Gizamlo® with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Warnings</em></p><p><u>Hypotension: volume-depleted patients:</u></p><p>Irbesartan has been rarely associated with hypotension in hypertensive patients without other co-morbid conditions. As with ACE inhibitors, symptomatic hypotension may be expected to occur in sodium / volume-depleted patients such as those treated vigorously with diuretics and /or salt restriction, or on hemodialysis. Volume and sodium-depletion should be corrected before initiating therapy with irbesartan / amlodipine combination or a lower starting dose should be considered.</p><p><u>Fetal / neonatal morbidity and mortality:</u></p><p>Although there is no experience with irbesartan in pregnant women, in utero exposure to ACE inhibitors given to pregnant women during the second and third trimesters of gestation has been reported to cause injury and death to the developing fetus. Thus, as for any drug that also acts directly on the renin &ndash;angiotensin-aldosterone system, irbesartan / amlodipine combination should not be used during pregnancy. If pregnancy is detected during therapy, irbesartan / amlodipine combination should be discontinued as soon as possible.</p><p><u>Patients with heart failure:</u></p><p>Amlodipine was associated with increase in pulmonary edema in patients with NYHA III and IV heart failure of non-ischemic etiology despite no significant difference in the incidence of worsening heart failure.</p><p><u>Hepatic impairment:</u></p><p>As with other calcium antagonists, amlodipine&#39;s half-life is prolonged in patients with impaired liver function and dosage recommendations have not been established. Irbesartan Amlodipine combination should therefore be administered with caution in these patients.</p><p><u>Hypertensive crises:</u></p><p>The safety and efficacy in Irbesartan /Amlodipine combination in hypertensive crises has not been established.</p><p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with aliskiren-</u></em><em> <u>containing medicinal products:</u> </em>the dual blockade of the renin-angiotensin-aldosterone system induced by administration of the Irbesartan/Amlodipine + aliskiren combination is not recommended as there is an increased risk of hypotension, hyperkalemia and impairment of renal function. Use of the Irbesartan/Amlodipine + aliskiren combination is contraindicated in patients with diabetes mellitus or with renal insufficiency (glomerular filtration rate [GFR] &lt;60 mL/min/1.73 m2).</p><p>As a consequence of blocking the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function is dependent on renin-angiotensin-aldosterone system activity (hypertensive patients with renal artery stenosis in one or both kidneys, or patients with severe congestive heart failure), treatment with other drugs that affect this system has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. The possibility of a similar effect occurring with the use of an angiotensin II receptor antagonist, including irbesartan, cannot be ruled out.</p><p><em>Geriatric use: </em>among patients who received irbesartan, no overall differences in efficacy or safety were observed between older patients (65 years or older) and younger patients.</p><p><em>Pediatric use: </em>safety and efficacy in pediatric patients have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For Irbesartan and amlodipine combination:</p><p>It was found that there is no pharmacokinetic interaction between irbesartan and amlodipine if they were given alone or in combination.</p><p>No information is available on drug interactions for irbesartan amlodipine combination with other medicinal products.</p><p>Irbesartan</p><p>No interactions would be expected to occur with drugs which metabolism depends on cytochrome P450 isoenzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1 or CYP3A4.</p><p>Irbesartan is primarily metabolized by CYP2C9, however, no significant pharmacodynamic interactions were observed when irbesartan was co-administered with warfarin (metabolized by CYP2C9).</p><p>The pharmacokinetic parameters of irbesartan are not affected by co-administration with nifedipine or hydrochlorothiazide.</p><p>Irbesartan does not affect the pharmacokinetics of simvastatin (metabolized by CYP3A4) or digoxin (substrate of P-glycoprotein efflux transporter).</p><p>Based on experience with the use of other drugs that act on the renin-angiotensin system, concomitant use of potassium &ndash; sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase serum potassium levels.</p><p>Use of <strong>Gizamlo</strong><strong>&reg; </strong>concomitantly with medicinal products containing aliskiren is contraindicated in patients with diabetes mellitus or moderate to severe renal insufficiency (glomerular filtration rate [GFR] &lt;60mL/ min/1.73m2), and is not recommended in other patients. In elderly patients, volume-depleted patients (including those treated with diuretics), or in patients with impaired renal function, co- administration of irbesartan with NSAIDs, including selective COX-2 inhibitors, or with angiotensin II receptor antagonists, including irbesartan, can cause deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Renal function should be monitored periodically in patients receiving occasional treatment with irbesartan and NSAIDs. The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.</p><p>Amlodipine:</p><p>Amlodipine has been safely co-administered with thiazide diuretics, beta blockers, alpha blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.</p><p>It was reported that amlodipine has no effect on the protein binding of studied medicines (digoxin, phenytoin, warfarin or indomethacin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine: co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grapefruit juice: Co-administration of 240 mL of grapefruit juice with a single 10 mg oral dose of amlodipine had no significant effect on the pharmacokinetics of Amlodipine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aluminum / magnesium (antacids): Concomitant administration of an antacid containing aluminum / magnesium with a single dose of amlodipine had no significant effect on the pharmacokinetic profile of amlodipine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sildenafil: when amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atorvastatin: co-administration of multiple 10 mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin: it was shown that co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin: co-administration of amlodipine did not change warfarin prothrombin response time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporine: it was shown that amlodipine does not significantly alter the pharmacokinetics of cyclosporine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy and lactation:</p><p><em>Pregnancy:</em></p><p>There are no adequate data in pregnant women. Irbesartan Amlodipine combination is contraindicated during pregnancy. <strong>Gizamlo</strong><strong>&reg; </strong>must not be administered to women of childbearing potential unless effective contraception is used. When pregnancy is detected during therapy with Irbesartan Amlodipine, treatment shall be discontinued as soon as possible.</p><p><em>Lactating mothers</em>:</p><p><strong>Gizamlo</strong><strong>&reg; </strong>is contraindicated during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machines. When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.</p><p>Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Because clinical trials are conducted under widely varying conditions, the incidence of adverse reaction observed in the clinical trials of one drug cannot be directly compared to that observed in the clinical trials of other drugs and may not reflect that observed in practice. Irbesartan has been evaluated for safety in clinical studies.</p><p>Adverse events in patients receiving irbesartan were generally mild and transient with no relationship to the dose. The incidence of adverse events was not related to age, gender or race.</p><p>The frequency of adverse events is defined using the following convention:</p><p>Very common ( 1/10); common ( 1/100 and &lt; 1/10); uncommon ( 1/1,000 and &lt; 1/100); rare ( 1/10,000 and &lt; 1/1,000); very rare (&lt; 1/10,000); unknown: no incidence data available.</p><table border="1" cellspacing="0" cellpadding="0" style="width:833px"><tbody><tr><td colspan="4" style="vertical-align:top; width:830px"><p><em>Table 1 &ndash; adverse events with irbesartan Clinical Trials or Postmarketing Reports</em></p></td></tr><tr><td style="vertical-align:top; width:216px"><p>&nbsp;</p></td><td style="vertical-align:top; width:103px"><p>Common (a)</p></td><td style="vertical-align:top; width:126px"><p>Uncommon (b)</p></td><td style="vertical-align:top; width:384px"><p>Unknown</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:384px"><p>Hypersensitivity</p><p>reactions</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Metabolism and</p><p>nutrition disorders</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:384px"><p>Hyperkalemia</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Nervous system</p><p>disorders</p></td><td style="vertical-align:top; width:103px"><p>Dizziness,</p><p>headache</p></td><td style="vertical-align:top; width:126px"><p>Postural dizziness</p></td><td style="vertical-align:top; width:384px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:126px"><p>Tachycardia</p></td><td style="vertical-align:top; width:384px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Respiratory, thoracic and mediastinal</p><p>disorders</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:126px"><p>Cough</p></td><td style="vertical-align:top; width:384px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:103px"><p>Nausea, vomiting</p></td><td style="vertical-align:top; width:126px"><p>Diarrhea, dyspepsia /</p><p>heartburn</p></td><td style="vertical-align:top; width:384px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:384px"><p>Jaundice, elevated</p><p>liver function tests, hepatitis</p></td></tr><tr><td style="vertical-align:top; width:216px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:103px"><p>&nbsp;</p></td><td style="vertical-align:top; width:126px"><p>&nbsp;</p></td><td style="vertical-align:top; width:384px"><p>Angioedema, urticaria</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Musculoskeletal</p><p>and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Impaired renal function including isolated cases of renal failure in</p><p>patients at risk</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sexual dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders</p><p>and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue, edema</p></td><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Asthenia</p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes all adverse events whether causal relationship to therapy is probable possible or unlikely, irrespective of incidence in the placebo-treated patients</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes all adverse events whether causal relationship to therapy is probable possible or unlikely, occurring with an incidence of 0.5% to &lt;1% and at similar or slightly increased incidence in irbesartan treated patients compared to placebo-treated patients (no statistically significant differences between the 2 treatment groups)</p><p><u>For amlodipine</u></p><p>Adverse events that have been reported in amlodipine are categorized below according to system organ class and frequency (see table 2).</p><p>The following CIOMS frequency rating is used, when applicable:</p><p>Very common (&nbsp; 1/10%); common (&nbsp; 1 and &lt; 10%); uncommon (&nbsp; 0.1 and &lt; 1%); rare ( 0.01 and &lt; 0.1%); very rare (&lt; 0.01%); unknown: cannot be estimated from available data.</p><table border="1" cellspacing="0" cellpadding="0" style="width:898px"><tbody><tr><td colspan="4" style="vertical-align:top; width:895px"><p><em>Table 2 &ndash; adverse events Reported in Amlodipine Clinical Trials</em></p></td></tr><tr><td style="vertical-align:top; width:204px"><p>&nbsp;</p></td><td style="vertical-align:top; width:153px"><p>Common</p></td><td style="vertical-align:top; width:255px"><p>Uncommon</p></td><td style="vertical-align:top; width:283px"><p>Very rare</p></td></tr><tr><td style="vertical-align:top; width:204px"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>lymphatic&nbsp;&nbsp;&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top; width:153px"><p>&nbsp;</p></td><td style="vertical-align:top; width:255px"><p>&nbsp;</p></td><td style="vertical-align:top; width:283px"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top; width:204px"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top; width:153px"><p>&nbsp;</p></td><td style="vertical-align:top; width:255px"><p>&nbsp;</p></td><td style="vertical-align:top; width:283px"><p>Allergic reactions</p></td></tr><tr><td style="vertical-align:top; width:204px"><p>Metabolism and</p><p>nutrition disorders</p></td><td style="vertical-align:top; width:153px"><p>&nbsp;</p></td><td style="vertical-align:top; width:255px"><p>&nbsp;</p></td><td style="vertical-align:top; width:283px"><p>Hyperglycemia</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Psychiatric</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia, mood</p><p>changes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness, headache, somnolence</p></td><td style="vertical-align:top"><p>Hypoesthesia, paresthesia, tremor, taste perversion,</p><p>syncope</p></td><td style="vertical-align:top"><p>Peripheral neuropathy</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual</p><p>disturbances</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acute Myocardial infarction, arrhythmia, ventricular tachycardia and</p><p>atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea, rhinitis</p></td><td style="vertical-align:top"><p>Coughing</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, abdominal pain</p></td><td style="vertical-align:top"><p>Dyspepsia, vomiting, altered bowel habits, dry</p><p>mouth</p></td><td style="vertical-align:top"><p>Pancreatitis, gastritis, gingival, hyperplasia</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis, jaundice, and hepatic enzyme elevations (mostly consistent with</p><p>cholestasis)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urticaria, Pruritus, purpura, increased sweating, skin discoloration,</p><p>alopecia</p></td><td style="vertical-align:top"><p>Angioedema, erythema multiforme, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia, muscle cramps, myalgia, back</p><p>pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased urinary</p><p>frequency,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:893px"><tbody><tr><td style="vertical-align:top; width:207px"><p>&nbsp;</p></td><td style="vertical-align:top; width:151px"><p>&nbsp;</p></td><td style="vertical-align:top; width:255px"><p>micturition</p><p>disorder, nocturia</p></td><td style="vertical-align:top; width:276px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:207px"><p>Reproductive</p><p>system and breast disorders</p></td><td style="vertical-align:top; width:151px"><p>Impotence, gynecomastia</p></td><td style="vertical-align:top; width:255px"><p>&nbsp;</p></td><td style="vertical-align:top; width:276px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:207px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:151px"><p>Fatigue, edema</p></td><td style="vertical-align:top; width:255px"><p>Chest pain, Asthenia, general malaise,</p><p>nonspecific pain</p></td><td style="vertical-align:top; width:276px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:207px"><p>Investigations</p></td><td style="vertical-align:top; width:151px"><p>&nbsp;</p></td><td style="vertical-align:top; width:255px"><p>Weight gain,</p><p>weight loss</p></td><td style="vertical-align:top; width:276px"><p>&nbsp;</p></td></tr></tbody></table><p>In clinical trials comparing the fixed-dose combination irbesartan/amlodipine to either irbesartan or amlodipine monotherapy, the types and incidences of treatment-emergent adverse events (TEAEs) possibly related to study treatment were similar to those observed earlier monotherapy clinical trials and postmarketing reports. The most frequently reported adverse event was peripheral edema, mainly associated with amlodipine (see table 3).</p><p>The following CIOMS frequency rating is used, when applicable:</p><p>Very common: &ge; 10 %; common: &ge; 1 and &lt; 10 %; uncommon: &ge; 0.1 % and &lt; 1%; rare;</p><p>&ge; 0.01 % and &lt; 0.1 %; very rare: &lt; 0.01 %, unknown (cannot be estimated from available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table 3 &ndash; Treatment-Emergent Adverse Events Considered Possibly Related to Study</p><p>Drug in Irbesartan/Amlodipine Clinical Studies.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Irbesartan monotherapy</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Upper abdominal pain, nausea, tongue</p><p>disorder</p></td><td style="vertical-align:top"><p>Diarrhea</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural</p><p>complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fall</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Amlodipine monotherapy</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration site conditions</p></td><td style="vertical-align:top"><p>Peripheral edema</p></td><td style="vertical-align:top"><p>Edema, facial edema</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:685px"><tbody><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:136px"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:233px"><p>Glossodynia</p></td><td style="vertical-align:top; width:136px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:233px"><p>Dizziness</p></td><td style="vertical-align:top; width:136px"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td style="vertical-align:top; width:233px"><p>Cough</p></td><td style="vertical-align:top; width:136px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous disorders</p></td><td style="vertical-align:top; width:233px"><p>Contact dermatitis</p></td><td style="vertical-align:top; width:136px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top; width:233px"><p>Hot flush</p></td><td style="vertical-align:top; width:136px"><p>Flushing</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:682px"><p><strong><em>Irbesartan / amlodipine fixed combination</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:233px"><p>Peripheral edema</p></td><td style="vertical-align:top; width:136px"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:136px"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:233px"><p>Palpitations</p></td><td style="vertical-align:top; width:136px"><p>Sinus bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:233px"><p>Dizziness, headache,</p><p>somnolence</p></td><td style="vertical-align:top; width:136px"><p>Paresthesia</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast</p><p>disorders</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:136px"><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:136px"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top; width:233px"><p>postural hypotension</p></td><td style="vertical-align:top; width:136px"><p>hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:233px"><p>Gingival swelling</p></td><td style="vertical-align:top; width:136px"><p>Nausea, upper abdominal</p><p>pain, constipation</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:233px"><p>Proteinuria</p></td><td style="vertical-align:top; width:136px"><p>Azotemia,</p><p>hypercreatinemia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:136px"><p>Hyperkalemia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:233px"><p>&nbsp;</p></td><td style="vertical-align:top; width:136px"><p>Joint stiffness, arthralgia,</p><p>myalgia</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>To report side effects:</strong></p><p>The National Pharmacovigilance Centre (NPC)</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966- 11-2038222, Ext 2317, 2356, 2340</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience in adults exposed to doses of up to 900 mg/day irbesartan for 8 weeks revealed no toxicity. No specific information is available on the treatment of overdose with irbesartan. Available data for amlodipine suggest that overdose could result in excessive peripheral vasodilatation and possibly reflex tachycardia, Marked and probably prolonged systemic hypotension and shock with fatal outcome have been reported.</p><p>The patient should be closely monitored and symptomatic and supportive treatment administered. Suggested measures include gastric lavage. Administration of activated charcoal to healthy subjects immediately or up to two hours after ingestion of amlodipine 10 mg has been shown to significantly decrease amlodipine absorption.</p><p>As amlodipine is highly protein bound and irbesartan is not removed from the body by hemodialysis, hemodialysis does not appear to be useful. If massive overdose should occur, active cardiac and respiratory monitoring should be initiated.</p><p>Frequent blood pressure measurement is essential.</p><p>Clinically significant hypotension due to amlodipine overdose calls for active cardiovascular support including elevation of the extremities and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.</p><p>Amlodipine is a calcium antagonist belonging to the dihydropyridine group which acts on the calcium channel binding sites. It causes prolonged inhibition of the entry of calcium via slow calcium channels into smooth muscles and myocardial cells.</p><p><u>Pharmacodynamic properties of Irbesartan</u></p><p>Pharmacotherapeutic group: Angiotensin-II antagonists, plain. ATC code: C09C A04.</p><p><u>Mechanism of action:</u> Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of</p><p>angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration. Serum potassium levels are not significantly affected by irbesartan alone at the recommended doses. Irbesartan does not inhibit ACE (kininase- II), an enzyme which generates angiotensin-II and also degrades bradykinin into inactive metabolites.</p><p>Irbesartan does not require metabolic activation for its activity. <u>Clinical efficacy</u></p><p><em>Hypertension</em></p><p>Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of 150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.</p><p>Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses. Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily dosing on the same total dose.</p><p>The blood pressure lowering effect of Irbesartan is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound hypertension has not been observed.</p><p>The blood pressure lowering effects of irbesartan and thiazide-type diuretics are additive. In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).</p><p>The efficacy of Irbesartan is not influenced by age or gender. As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy. When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.</p><p>There is no clinically important effect on serum uric acid or urinary uric acid secretion.</p><p><em>Paediatric population</em></p><p>Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant difference was apparent between these doses. Adjusted mean change of trough seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).</p><p><em>Hypertension and type 2 diabetes with renal disease</em></p><p>The &ldquo;Irbesartan Diabetic Nephropathy Trial (IDNT)&rdquo; shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double blind, controlled, morbidity and mortality trial comparing Irbesartan, amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes, proteinuria &ge; 900 mg/day and serum creatinine ranging from 1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Irbesartan on the progression of renal disease and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300 mg Irbesartan, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated.</p><p>Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of &le; 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group reached this target blood pressure whereas this figure was 76% and 78% in the irbesartan and amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or allcause mortality. Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.</p><p>Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it. As for the secondary endpoint of fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall population, although an increased incidence of non-fatal MI was seen for women and a decreased incidence of non-fatal MI was seen in males in the irbesartan group versus the placebo-based regimen. An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the overall population. However, no proper explanation for these findings in women has been identified.</p><p>The study of the &ldquo;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus (IRMA 2)&rdquo; shows that irbesartan 300 mg delays progression to overt proteinuria in patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine &le; 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects (2 years) of Irbesartan on the progression to clinical (overt) proteinuria (urinary albumin excretion rate (UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood pressure goal was &le; 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the glomerular filtration rate (GFR) was not observed during the first three months of treatment. The slowing in the progression to clinical proteinuria was evident as early as three months and continued over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the Irbesartan 300 mg group (34%) than in the placebo group (21%).</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers. ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><u>Pharmacodynamic properties of Amlodipine</u></p><p><em>Pharmacotherapeutic group</em>: calcium channel blockers &ndash; Dihydropyridine derivatives. <em>ATC code</em>: C08CA01.</p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</p><p>&bull;&nbsp; The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p><u>Use in patients with coronary artery disease (CAD)</u></p><p>The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multicente, randomized, double-blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT). Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10-20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, betablockers, diuretics and aspirin, for 2 years. The key efficacy results are presented in Table 1. The results indicate that amlodipine treatment was associated with fewer hospitalizations for angina and revascularization procedures in patients with CAD.</p><table border="1" cellspacing="0" cellpadding="0" style="width:627px"><tbody><tr><td colspan="6" style="vertical-align:top; width:624px"><p><strong>Table 1. Incidence of significant clinical outcomes for CAMELOT</strong></p></td></tr><tr><td style="vertical-align:top; width:245px"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top; width:221px"><p><u>Cardiovascular event rates, No. (%)</u></p></td><td colspan="2" style="vertical-align:top; width:159px"><p><u>Amlopidine vs. Placebo</u></p></td></tr><tr><td style="vertical-align:top; width:245px"><p>Outcomes</p></td><td style="vertical-align:top; width:72px"><p>Amlopidine</p></td><td style="vertical-align:top; width:74px"><p>Placebo</p></td><td style="vertical-align:top; width:74px"><p>Enalapril</p></td><td style="vertical-align:top; width:108px"><p>Hazard&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ratio (95% CI)</p></td><td style="vertical-align:top; width:46px"><p><em>P </em>Value</p></td></tr><tr><td style="vertical-align:top; width:245px"><p><u>Primary Endpoint</u></p></td><td style="vertical-align:top; width:72px"><p>&nbsp;</p></td><td style="vertical-align:top; width:74px"><p>&nbsp;</p></td><td style="vertical-align:top; width:74px"><p>&nbsp;</p></td><td style="vertical-align:top; width:108px"><p>&nbsp;</p></td><td style="vertical-align:top; width:46px"><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:236px"><p>Adverse cardiovascular events</p></td><td style="vertical-align:top; width:82px"><p>110 (16.6)</p></td><td style="vertical-align:top"><p>151 (23.1)</p></td><td style="vertical-align:top"><p>136 (20.2)</p></td><td style="vertical-align:top"><p>0.69 (0.54-0.88)</p></td><td style="vertical-align:top"><p>.003</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><u>Individual Components</u></p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Coronary revascularization</p></td><td style="vertical-align:top; width:82px"><p>78 (11.8)</p></td><td style="vertical-align:top"><p>103 (15.7)</p></td><td style="vertical-align:top"><p>95 (14.1)</p></td><td style="vertical-align:top"><p>0.73 (0.54-0.98)</p></td><td style="vertical-align:top"><p>.03</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Hospitalization&nbsp;&nbsp;&nbsp;&nbsp; for angina</p></td><td style="vertical-align:top; width:82px"><p>51 (7.7)</p></td><td style="vertical-align:top"><p>84 (12.8)</p></td><td style="vertical-align:top"><p>86 (12.8)</p></td><td style="vertical-align:top"><p>0.58 (0.41-0.82)</p></td><td style="vertical-align:top"><p>.002</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Nonfatal MI</p></td><td style="vertical-align:top; width:82px"><p>14 (2.1)</p></td><td style="vertical-align:top"><p>19 (2.9)</p></td><td style="vertical-align:top"><p>11 (1.6)</p></td><td style="vertical-align:top"><p>0.73 (0.37-1.46)</p></td><td style="vertical-align:top"><p>.37</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Stroke or TIA</p></td><td style="vertical-align:top; width:82px"><p>6 (0.9)</p></td><td style="vertical-align:top"><p>12 (1.8)</p></td><td style="vertical-align:top"><p>8 (1.2)</p></td><td style="vertical-align:top"><p>0.50 (0.19-1.32)</p></td><td style="vertical-align:top"><p>.15</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Cardiovascular death</p></td><td style="vertical-align:top; width:82px"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>2 (0.3)</p></td><td style="vertical-align:top"><p>5 (0.7)</p></td><td style="vertical-align:top"><p>2.46 (0.48-12.7)</p></td><td style="vertical-align:top"><p>.27</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Hospitalization&nbsp;&nbsp;&nbsp;&nbsp; for CHF</p></td><td style="vertical-align:top; width:82px"><p>3 (0.5)</p></td><td style="vertical-align:top"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top"><p>0.59 (0.14-2.47)</p></td><td style="vertical-align:top"><p>.46</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Resuscitated cardiac arrest</p></td><td style="vertical-align:top; width:82px"><p>0</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top"><p>1 (0.1)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>.04</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>New-onset peripheral&nbsp;&nbsp;&nbsp;&nbsp; vascular disease</p></td><td style="vertical-align:top; width:82px"><p>5 (0.8)</p></td><td style="vertical-align:top"><p>2 (0.3)</p></td><td style="vertical-align:top"><p>8 (1.2)</p></td><td style="vertical-align:top"><p>2.6 (0.50-13.4)</p></td><td style="vertical-align:top"><p>.24</p></td></tr></tbody></table><p>Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.</p><p><u>Use in patients with heart failure:</u></p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-</p><p>IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.</p><p>A placebo-controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.</p><p>In a follow-up, long term, placebo-controlled study (PRAISE-2) of Amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.</p><p><u>Treatment to prevent heart attack trial (ALLHAT):</u></p><p>A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide- diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% % vs 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89- 1.02] p=0.20.</p><p><u>Use in children (aged 6 years and older):</u></p><p>In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5mg dose, and 5.0mg dose of amlodipine with placebo, showed that both doses reduced Systolic Blood Pressure significantly more than placebo. The difference between the two doses was not statistically significant.</p><p>The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood have also not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic properties of Irbesartan</u> <u>Absorption</u></p><p>After oral administration, irbesartan is well absorbed: studies of absolute bioavailability</p><p>gave values of approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of irbesartan.</p><p><u>Distribution</u></p><p>Plasma protein binding is approximately 96%, with negligible binding to cellular blood components. The volume of distribution is 53 - 93 litres.</p><p><u>Biotransformation</u></p><p>Following oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan. Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating metabolite is irbesartan glucuronide (approximately 6%). <em>In vitro </em>studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.</p><p><u>Linearity/non-linearity</u></p><p>Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 - 176 and 3 - 3.5 ml/min, respectively. The terminal elimination half-life of irbesartan is 11 - 15 hours.</p><p>Steady-state plasma concentrations are attained within 3 days after initiation of a once- daily dosing regimen. Limited accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan were observed in female hypertensive patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater in older subjects (&ge; 65 years) than those of young subjects (18 - 40 years).</p><p>However the terminal half-life was not significantly altered. No dosage adjustment is necessary in older people.</p><p><u>Elimination</u></p><p>Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</p><p><u>Paediatric population</u></p><p>The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults (twelve children over 12 years, nine children between 6 and 12 years). Results showed that Cmax, AUC and clearance rates were comparable to those observed in adult patients receiving 150 mg irbesartan daily. A limited accumulation of irbesartan (18%) in plasma was observed upon repeated once daily dosing.</p><p><u>Renal impairment</u></p><p>In patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered. Irbesartan is not removed by haemodialysis.</p><p><u>Hepatic impairment</u></p><p>In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.</p><p>Studies have not been performed in patients with severe hepatic impairment.</p><p><u>Pharmacokinetic properties of Amlodipine</u></p><p>Absorption, distribution, plasma protein binding</p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/kg. <em>In vitro </em>studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p>Biotransformation/elimination</p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p>Hepatic impairment</p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p>Paediatric population</p><p>A population PK study has been conducted in 74 hypertensive children aged from 1 to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3 L/hr respectively in females. Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.</p><p>Elderly population</p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increase in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp;&nbsp; <u>Irbesartan</u><u>:</u></p><p>No carcinogenic evidence was observed with administration of irbesartan at doses of up to 500/1000 mg/kg/day in rats (male/female, respectively) and 1000 mg/kg/day in mice for 2 years. These doses provided a systemic exposure 4-25 times (rats) and 4-6 times (mice) the exposure in humans receiving 300 mg/day. Irbesartan was not mutagenic in a battery of in vitro tests (Ames microbial test, rat hepatocyte DNA repair test, V79 mammalian-cell forward gene-mutation assay). Irbesartan was negative in several tests for induction of chromosomal aberrations (in vitro human lymphocyte assay; in vivo mouse micronucleus study). Fertility and reproductive performance were not affected in studies of male and female rats, even at doses causing some parental toxicity (up to 650 mg/kg/day).</p><p>No significant effects on the number of corpora lutea, implants, or live fetuses were observed. Irbesartan had no effect on survival, development, or reproduction of offspring.</p><p>Transient toxic effects (increased renal pelvic cavitation, hydroureter or subcutaneous edema) were observed in rat fetuses at doses of 50 mg/kg/day or higher, which resolved after birth. In rabbits, maternal mortality, abortion and early resorption were observed at doses of 30 mg/kg/day.</p><p>No other teratogenic effects were observed in rats or rabbits.</p><p><strong><u>Amlodipine:</u></strong></p><p>Carcinogenesis: Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25 and 2.5 mg/kg/day showed no evidence of carcinogenicity, The highest dose (similar to the maximum recommended human dose of 10 mg on a mg/m2 basis for mice, and about twice* this maximum dose for rats) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenesis: Mutagenesis studies revealed no amlodipine - related effects at either the gene or chromosome levels.</p><p>Infertility: There was no effect on fertility in rats treated with amlodipine at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis).</p><p>* (based on a 50 kg patient)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The inactive ingredients are: Croscarmellose sodium, microcrystalline cellulose, hypromellose, colloidal anhydrous Silica, magnesium stearate, polyethylene glycol and titanium dioxide. <strong>Gizamlo</strong><strong>&reg; 150mg/10mg </strong>contains red iron oxide (E172). <strong>Gizamlo</strong><strong>&reg; 300mg/5mg </strong>contains yellow iron oxide (E172)<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packs of 30 film coated tablets.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Outer packaging</strong></p></td><td style="vertical-align:top"><p><strong>Immediate packaging</strong></p></td></tr><tr><td style="vertical-align:top"><p>Carton</p><p>Leaflet</p></td><td style="vertical-align:top"><p>Laminated Aluminum Strip</p><p>for formpack</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O. Box 9364
Na’ur – Amman – Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>